ReviewRheumatology international2013
Leflunomide: friend or foe for systemic lupus erythematosus?
Review in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.PloS one · 2015Pooled it
- The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.Drugs in R&D · 2019Trial
- Refractory lupus nephritis: current Understanding and emerging treatment strategies.Clinical and experimental medicine · 2025Review
- The key player in the pathogenesis of environmental influence of systemic lupus erythematosus: Aryl hydrocarbon receptor.Frontiers in immunology · 2022Review
- 2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus.Rheumatology and immunology research · 2020Article
- A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.Journal of veterinary internal medicine · 2017Article
- Current and emerging treatment options in the management of lupus.ImmunoTargets and therapy · 2016Review
- Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus.Journal of immunology research · 2015Article
- The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?: Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33(2):273-6.Rheumatology international · 2014Article
- Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Clinical rheumatology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.
Indexed as
Identifiers
22961090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.